FDA Tunes Up Medical Device Advice Forms
Published Date: 2/18/2026
Notice
Summary
The FDA wants your thoughts on how they collect info for their Q-Submission and Early Payor Feedback programs, which help medical device makers get advice early on. These updates aim to make the process smoother for companies working with the FDA, saving time and possibly money. If you’re involved in medical device development, speak up by March 20, 2026, to help shape these important tools!
Analyzed Economic Effects
5 provisions identified: 3 benefits, 2 costs, 0 mixed.
Large Paperwork Hour Increase
If you make or sponsor medical devices, FDA estimates the information collection will total 864,418 hours annually and reports an overall increase of 451,180 hours and 4,535 responses per year. The agency requests comments by March 20, 2026.
eSTAR Voluntary Electronic Submission Option
FDA has an electronic Submission Template and Resource (eSTAR) for Q-Submissions that is currently voluntary. Q-Submissions using eSTAR are shown with an average burden of 69 hours per response and an eSTAR setup burden of 0.08 hours (5 minutes) per respondent.
MDDT Submissions Tracked Separately
Medical Device Development Tool (MDDT) submissions are now tracked as a distinct collection instrument under the MDDT guidance; FDA estimates 50 MDDT submissions annually with an average burden of 137 hours each (6,850 hours total). FDA states the submission instructions are otherwise unchanged and that there is no new collection occurring in this revision.
Early Payor Feedback Form Burden
Manufacturers may request payor organizations join Pre-Submission meetings through the Early Payor Feedback Program using a voluntary form. FDA estimates the manufacturer request form takes 2 hours per response and estimates 35 such responses annually (70 hours total).
No Capital or O&M Costs Reported
FDA states there are no capital costs or operating and maintenance costs associated with this information collection. The burden estimates reflect only respondent time.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-16959, Frequently Asked Questions-Developing Potential Cellular and Gene Therapy Products; Final Guidance for Industry; Availability
The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance titled "Frequently asked Questions--Developing Potential Cellular and Gene Therapy Products." The guidance document provides industry with answers to frequently asked questions (FAQs) and commonly faced issues that arise during the development of cellular and gene therapy (CGT) products. The FAQs represent common questions directed to the Agency and span multiple disciplines, including regulatory review; chemistry, manufacturing, and controls (CMC); pharmacology/toxicology; clinical; and clinical pharmacology. This guidance announced in this notice finalizes the draft guidance of the same title issued on November 19, 2024.
2026-16942, Food Additives Permitted in Feed and Drinking Water of Animals; Chromium DL-methionine Chelate
The Food and Drug Administration (FDA, we, or the Agency) is amending the regulations for food additives permitted in feed and drinking water of animals to provide for the safe use of chromium DL- methionine chelate as a nutritional source of chromium in cattle feed. This action is in response to a food additive petition filed by Zinpro Corp.
2026-16939, GNT USA, LLC.; Filing of Color Additive Petition
The Food and Drug Administration (FDA or we) is announcing that we have filed a petition, submitted by GNT USA, LLC., c/o Exponent, Inc., proposing that we amend our color additive regulations to provide for the safe use of safflower (Carthamus tinctorius L.) extract as a color additive in various foods at levels consistent with good manufacturing practices.
Previous / Next Documents
Previous: 2026-03095, Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Generic Clearance for Quick Turnaround Testing of Communication Effectiveness
The FDA is asking for approval to keep quickly testing how well their food safety messages work. This helps them make sure the public and food suppliers understand important safety info fast. If you want to share your thoughts, you have until March 20, 2026, to comment—no big costs or delays, just smarter communication!
Next: 2026-03097, Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Electronic Products Requirements
The FDA is updating its paperwork rules for electronic products that emit radiation to keep everyone safe. If you make or sell these products, you might need to provide some info to the government. Comments on these changes are open until March 20, 2026, so now’s the time to speak up!